Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP inhibitor resistance in IDH1-mutant cancers due to loss of end protection factors, 53BP1 and REV7.

NAR cancer - 1 Dec 2025

Colón-Ríos Daniel Andrés, Dow Jonathan, Krysztofiak Adam, Liu Yanfeng, Rogers Faye A, Glazer Peter M

Abstract excerpt

Acquired resistance presents a major challenge for targeted therapies, with initially responsive tumors eventually reverting underlying vulnerabilities. Our group recently reported that cancers harboring isocitrate dehydrogenase 1/2 (IDH1/2) mutations have defective recruitment of homology-directed repair (HDR) factors to sites of DNA damage and consequent sensitivity to poly(ADP-ribose) polymerase inhibitors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isocitrate Dehydrogenase

Share to Neoplasms

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Tumor Suppressor p53-Binding Protein 1

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 41357766
DOI: 10.1093/narcan/zcaf047
PMCID: PMC12675010

Genes

IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP inhibitor resistance in IDH1-mutant cancers due to loss of end protection factors, 53BP1 and REV7.PMID 41357766Read ↗

Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage responseSemantic proximity Read ↗

IDH-Mutant Tumors Vulnerable to PARP Inhibition.Semantic proximity Read ↗

ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forksSemantic proximity Read ↗

Heterochromatin-Dependent Replication Stress: A Lesson from IDH1/2 Mutants.Semantic proximity Read ↗

Mechanisms of PARP inhibitor resistance in ovarian cancerSemantic proximity Read ↗

Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitorsSemantic proximity Read ↗

ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forksSemantic proximity Read ↗

Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1 -Deficient CellsSemantic proximity Read ↗

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in <i>BRCA1/2</i> -mutant metastatic breast cancerSemantic proximity Read ↗

Drug-gene interaction screens coupled to tumour data analyses identify the most clinically-relevant cancer vulnerabilities driving sensitivity to PARP inhibitionSemantic proximity Read ↗

Oncogenic IDH mutations increase heterochromatin-related replication stress without impacting tumor mutation burdenSemantic proximity Read ↗

Replication Fork Remodeling and Therapy Escape in DNA Damage Response-Deficient CancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.